Browse News

Found 226 articles

• Kura Oncology to Participate in Cantor Global Healthcare Conference 2023

  9/19/2023

  Kura Oncology, Inc. today announced its participation in the upcoming Cantor Global Healthcare Conference 2023 being held in New York. Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in a fireside chat at 10:55 a.m. ET / 7:55 a.m. PT on September 26, 2023.

• Life Science Cares Announces Impact Level Partnership with Kura Oncology

  9/7/2023

  Life Science Cares is thrilled to announce a new $250,000 partnership with Kura Oncology to provide additional grant funding for educational initiatives in both San Diego and Greater Boston.

• Kura Oncology Appoints Brian Powl as Chief Commercial Officer

  8/14/2023

  Kura Oncology, Inc. today announced the appointment of Brian Powl as Chief Commercial Officer.

• Kura Oncology Reports Second Quarter 2023 Financial Results

  8/3/2023

  Kura Oncology, Inc. reported second quarter 2023 financial results and provided a corporate update.

• Kura Oncology to Report Second Quarter 2023 Financial Results

  7/27/2023

  Kura Oncology, Inc. today announced that it will report second quarter 2023 financial results after the close of U.S. financial markets on Thursday, August 3, 2023.

• 

  FDA Puts Clinical Hold on Hemogenyx’s CAR-T AML Therapy

  7/10/2023

  The biotech Monday announced a clinical hold on its HEMO-CAR-T candidate, which is being trialed for the treatment of acute myeloid leukemia, due to manufacturing concerns cited by the regulator.
• 

  Kura Hopes to Raise $100M in Public Offering on Heels of Clinical Data

  6/14/2023

  The biopharma company’s plan to issue and sell $100 million of shares of its common stock comes just days after releasing late-breaking Phase I/II data for menin inhibitor ziftomenib.

• Kura Oncology Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants

  6/14/2023

  Kura Oncology, Inc., a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, announced the pricing of an underwritten public offering of common stock and pre-funded warrants.

• Kura Oncology Announces Commencement of Public Offering of Common Stock and Pre-Funded Warrants

  6/13/2023

  Kura Oncology, Inc. announced that it has commenced an underwritten public offering, subject to market and other conditions, to issue and sell $100,000,000 of shares of its common stock.

• POINT Biopharma Announces Appointment of Dr. Bridget Martell to its Board of Directors

  6/12/2023

  POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to life-changing radiopharmaceuticals, today announced the filling of its vacant board seat with the appointment of Bridget Martell, M.A., M.D. to its Board of Directors.

• Kura Oncology Presents Late-Breaking Clinical Data for Menin Inhibitor Ziftomenib at 2023 European Hematology Association (EHA) Congress

  6/11/2023

  Kura Oncology, Inc. announced updated clinical data from KOMET-001, a Phase 1/2 clinical trial of the Company’s potent and selective menin inhibitor, ziftomenib, including significant clinical activity in patients with heavily pretreated and co-mutated relapsed/refractory NPM1-mutant acute myeloid leukemia.

• Kura Oncology Announces Late-Breaking Abstract Accepted for Oral Presentation at the 2023 European Hematology Association (EHA) Congress

  5/30/2023

  Kura Oncology, Inc. today announced that a late-breaking abstract with updated data from the Phase 1 trial of the Company’s menin inhibitor, ziftomenib, has been accepted for oral presentation at the 2023 European Hematology Association (EHA) Congress in Frankfurt, Germany.

• Kura Oncology to Participate in Two Upcoming Investor Conferences - May 23, 2023

  5/23/2023

  Kura Oncology, Inc. today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in the following events at upcoming investor conferences.

• Kura Oncology Reports First Quarter 2023 Financial Results

  5/10/2023

  Kura Oncology, Inc., a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, reported first quarter 2023 financial results and provided a corporate update.

• Kura Oncology to Participate in JMP Securities Life Sciences Conference

  5/9/2023

  Kura Oncology, Inc. today announced its participation in the JMP Securities Life Sciences Conference in New York.

• Kura Oncology to Report First Quarter 2023 Financial Results

  5/3/2023

  Kura Oncology, Inc. today announced that it will report first quarter 2023 financial results after the close of U.S. financial markets on Wednesday, May 10, 2023.

• Kura Oncology to Participate in Stifel Targeted Oncology Days

  4/18/2023

  Kura Oncology, Inc. today announced its participation in Stifel 2023 Targeted Oncology Days. Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in a virtual fireside chat at 1:00 p.m. ET / 10:00 a.m. PT on April 25, 2023.

• Kura Oncology Reports Preclinical Data Highlighting Synergistic Activity of Farnesyl Transferase Inhibitor in Combination with Targeted Therapies

  4/17/2023

  Kura Oncology, Inc. today reported preclinical data supporting the potential use of farnesyl transferase inhibitors (FTIs) to treat various types of solid tumors in combination with targeted therapies, including KRASG12C inhibitors and anti-angiogenic tyrosine kinase inhibitors (TKIs).

• Kura Oncology Announces Acceptance of Two Abstracts for Presentation at AACR Annual Meeting

  3/14/2023

  Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that two abstracts have been accepted for presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting, to be held in Orlando from April 14-19, 2023.

• Kura Oncology to Participate in Upcoming Investor Conferences

  3/1/2023

  Kura Oncology, Inc. today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in the following events at upcoming investor conferences.